
COVID Conversations: Dexamethasone and the RECOVERY Trials
Peter Horby, Professor of Emerging Infectious Diseases, and Martin Landray, Professor of Medicine and Epidemiology, both at Oxford's Nuffield Departments, discuss the RECOVERY trial they helped establish in March 2020 to test potential COVID-19 treatments through randomised clinical trial design. They cover how the trial identified low-dose dexamethasone as the first drug shown to improve survival in COVID-19 patients, explaining the trial's methodology and why randomisation mattered for separating real treatment effects from chance. The two researchers walk through what the data showed, which patient groups benefited, and how the finding changed clinical practice internationally within weeks of publication. They also discuss the trial's ongoing search for additional treatments, giving a working view of how large-scale clinical research got built and run under pandemic pressure.